P410: COMBINING MENIN AND MEK INHIBITION TO TREAT CHILDREN WITH POOR PROGNOSTIC KMT2A-R RAS-MUTANT ACUTE LEUKEMIA

• Nastassja Scheidegger,
• Gabriela Alexe,
• Delan Khalid,
• Jennifer Perry,
• Scott Armstrong,
• Yana Pikman,
• Kimberly Stegmaier

Affiliations

Nastassja Scheidegger

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Gabriela Alexe

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Delan Khalid

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Jennifer Perry

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Scott Armstrong

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Yana Pikman

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States

Kimberly Stegmaier

1 Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Oncology, Boston, United States